Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorNabiqasim Industries (Pvt) Ltd
About this trial
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Eligibility criteria
Qualifiers
Patients of any gender
Patients aged between 18-80 years
Patients having HbA1c 8 % or above
Patients diagnosed with type II diabetes (more than at least 06 months)
Disqualifiers
Patients with age less than 18
Patients with Type-I diabetes
Patients having diabetes for less than 06 months
Patients on GLP-1 and GIP
Trial design
Treatments tested in this trial
- Empagliflozin+Linagliptin+Metformin
Treatment groups
800 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov